Fundraising Fox
Simmunome Inc.
4 known investors
Find your way into Simmunome Inc.
Sign up to see every warm intro you have to Simmunome Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Simmunome Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Simmunome provides computational biology and mechanistic modeling solutions for drug development across all phases, helping pharmaceutical companies understand disease pathways, validate drug targets, predict efficacy, and optimize patient stratification.
Investors · 4
BKR Capitallisted by BKR CapitalToronto
How we know: BKR Capital's portfolio page · Not right? Tell us
Front Row Ventureslisted by Front Row VenturesMontreal
How we know: Front Row Ventures's portfolio page · Not right? Tell us
Related companies · 10
NucleomeNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
SequomeSequome uses AI to engineer biological sequences for developing therapeutics, based on its sequence-to-function model called Gene Genie. The company has collaborated with large pharmaceutical firms and Google DeepMind in the drug discovery and biotechnology space.
CellanomeCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Alterome Therapeutics, Inc.Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.
Noveome BiotherapeuticsNoveome is a clinical-stage biopharmaceutical company developing ST266, a multi-targeted secretome containing hundreds of biologically active proteins designed for neuroprotection, inflammation modulation, and tissue healing. The company is investigating ST266's potential across ophthalmology, neurology, dermatology, and other therapeutic areas.
FreenomeFreenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.
SensomeSensome develops medical technology solutions at the intersection of engineering and life sciences, focusing on healthcare applications.
EtiomeEtiome develops stage-specific medicines by applying single-cell omics and artificial intelligence to map disease progression and identify disease-modifying targets at early biological inflection points for preemptive intervention. Founded in 2021 out of Flagship Pioneering's Preemptive Health and Medicine initiative, the biotech company focuses on treating or reversing disease before it advances to later stages.
CelldomCellDom develops CloneXplorer, a live single-cell assay platform combining functional imaging, molecular readouts, and integrated cell retrieval for high-resolution cell analysis. The platform enables CAR T-cell potency testing, antibody/TCR discovery, cell line development, and precision medicine applications for research and therapeutic development teams.
Companies working in the same space as Simmunome Inc..
Frequently asked questions
- What does Simmunome Inc. do?
- Simmunome provides computational biology and mechanistic modeling solutions for drug development across all phases, helping pharmaceutical companies understand disease pathways, validate drug targets, predict efficacy, and optimize patient stratification.
- Who are Simmunome Inc.'s investors?
- Simmunome Inc.'s investors include BKR Capital, Front Row Ventures, Sandpiper Ventures, Scale Shift Ventures.